Clinical Trials Directory

Trials / Unknown

UnknownNCT05354076

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo

Status
Unknown
Phase
Phase 2
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Fudan University · Academic / Other
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

To study the correlation between the content of natural IgM in patients' blood samples and liposomal doxorubicin for clinical use, and to explore the possibility of using natural IgM content to guide clinical accurate medication.

Conditions

Interventions

TypeNameDescription
DRUGdoxorubicin hydrochloride liposome injectionAccording to the clinical diagnosis and treatment norms, it is suitable for patients with advanced malignant tumors diagnosed by histopathology with doxorubicin hydrochloride liposome injection chemotherapy.(For breast cancer patients: liposomal doxorubicin 35mg/m2 q3w)

Timeline

Start date
2000-03-01
Primary completion
2022-06-01
Completion
2022-11-01
First posted
2022-04-29
Last updated
2022-04-29

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT05354076. Inclusion in this directory is not an endorsement.

Study on the Correlation Between Immunoglobulin and Liposomal Doxorubicin in Vivo (NCT05354076) · Clinical Trials Directory